Press Release: ECCO 2025: new duvakitug data reinforce

From GlobeNewswire: 2025-02-22 02:30:00

New detailed data from the RELIEVE UCCD study show promising results for duvakitug in treating ulcerative colitis and Crohn’s disease. In the UC cohort, patients treated with duvakitug achieved higher rates of clinical remission compared to placebo, with significant response rates seen in advanced therapy-experienced and naïve patients. In the CD cohort, endoscopic response rates were higher with duvakitug versus placebo in both patient subgroups. Safety data showed duvakitug was well tolerated with no significant safety concerns. These findings support the potential of duvakitug as a new treatment option for patients with IBD.

The RELIEVE UCCD study presented by Sanofi and Teva Pharmaceuticals at the ECCO 2025 congress showcased the efficacy and safety of duvakitug, a human IgG1-λ2 monoclonal antibody targeting TL1A, in patients with moderate-to-severe UC and CD. Results demonstrated significant improvements in clinical and endoscopic outcomes, paving the way for a phase 3 program to start in H2 2025. Walter Reinisch, MD, PhD, lead investigator of the study, expressed optimism about the treatment response observed in the study, highlighting the potential of duvakitug to transform IBD treatment.

These findings provide hope for patients suffering from UC and CD, offering the potential for improved clinical outcomes and quality of life. With duvakitug showing promising results in the RELIEVE UCCD study, there is optimism for the development of a new treatment option for individuals with IBD.



Read more at GlobeNewswire: Press Release: ECCO 2025: new duvakitug data reinforce